AbbVie
Trade AbbVie 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About ABBV
AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders, such as Parkinson's, metabolic, comprising thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions.
ABBV Key Statistics
ABBV News
...
As more economists raise their recession forecast and consumer sentiment wanes, wrinkles and thin lips might be the least of our worries. AbbVie, the largest B...
recently announced its first-quarter earnings, reporting increased sales year-on-year while experiencing a decline in net income and earnings per share. Alongsi...
Analyst ratings
62%
of 29 ratingsMore ABBV News
AbbVie Inc.'s ABBV stock is trading higher after it released better-than-expected Q1 earnings and raised its 2025 forecast. The company reported an adjusted EP...
AbbVie rises as it beats Wall Street estimates, raises 2025 outlook AbbVie raised its profit outlook for 2025 after reporting sales and profit that beat Wall S...
William Blair analyst Matt Phipps has maintained their bullish stance on ABBV stock, giving a Buy rating on April 22. Matt Phipps has given his Buy rating due...
Biopharmaceutical company AbbVie (ABBV) saw its stock jump on Friday following the release of its Q1 2025 earnings report. The company reported adjusted diluted...
U.S. stock futures traded mixed on Friday after three consecutive days of gains, with S&P 500 futures edging higher amid rising earnings optimism and signs of e...
On CNBC's “Halftime Report Final Trades,” Joshua Brown, CEO and co-founder, Ritholtz Wealth Management, said he is staying long on 3M Company MMM. Supporting h...
Cantor Fitzgerald initiated coverage on AbbVie Inc ABBV, citing the company’s compelling mix of growth and defense with a differentiated topline profile, good v...
